To the Editor Immune checkpoint inhibitor (ICI) rechallenge is increasingly attracting attention. Making full use of immunotherapies is necessary to maximize the curative effect given our current understanding. In a recently published article, Dolladille and colleagues1 reported the recurrence rate of initial immune-related adverse events (irAEs) after an ICI rechallenge. Their study included all types of cancer and multiple ICI regimens based on the VigiBase database and found a 28.8% recurrence rate of the same irAE after rechallenge with the same ICI.1 While this was undoubtedly rigorously conducted and informative, there are several concerns that must be addressed.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Liu J, Yu J, Meng X. Recurrence of Immune-Related Adverse Events After Immune Checkpoint Inhibitor Rechallenge. JAMA Oncol. 2020;6(11):1813–1814. doi:10.1001/jamaoncol.2020.3955
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: